For 23 years, I was an attorney in the Division of Investment Management at the U.S. Securities and Exchange Commission in Washington, D.C. I retired in 2014.
I became interested in medical research while researching treatment options for my then-teenage daughter, who has heterozygous familial hypercholesterolemia, a genetic disease that causes very high LDL-cholesterol. I am a member of the Walking Gallery of Healthcare. In addition, I am a member/administrator of the Familial Hypercholesterolemia (FH) Discussion Group on Facebook (https://www.facebook.com/#!/groups/47098836197/). In September 2013, I became a member of the editorial board of Circulation: Cardiovascular Quality and Outcomes, one of the American Heart Association journals. I help edit a series of articles by patients or their family members (listed here). I am also a patient reviewer for BMJ and a member of the stakeholder engagement committee for C3FIT, a trial of post-stroke care, funded by PCORI. I am a member of the Society for Participatory Medicine.
Contact me at mannm at comcast.net. Follow me on Twitter @MarilynMann.
Comments without a valid email address will be deleted.
Disclosures: My husband and I have invested primarily in the Thrift Savings Plan and in mutual funds. However, after my mother died in March 2020, I inherited some individual stocks and bonds, including some stocks and bonds issued by certain drug and device manufacturers and a health insurance company. Some of these securities were held in an IRA or received a step-up in basis at my mother’s death, and I was able to sell them without major tax consequences. However, some of these securities received a step-up in basis at my father’s death in 2006 and did not receive another step-up in basis at my mother’s death. Selling these latter securities will cause me to incur large capital gains. According, my plan is to sell them over the next couple of years, to spread out the capital gains taxes. As of September 2021, I own stock in Abbott Laboratories, Johnson & Johnson, and Stryker Corp. Update: in January 2022, I sold my remaining shares in Abbott Labs, Johnson & Johnson, and Stryker.
Undate November 2022. Unfortunately, my brother Andrew passed away in March 2022. I inherited some health care related stocks from him, namely Abbott Labs, Johnson & Johnson, Stryker, and United Healthcare. I sold these stocks immediately after they were transferred to my account in October 2022.
Hi Marilyn, I’m writing because I wanted to show and offer you a new tool we just launched at FindTheBest that helps those innovating in the bio and health industries find VC firms that focus primarily on that space. I thought it might make a really cool tool to share readers because it can help find where you might want to take your pitch, and is a great way to help foster healthcare innovation.
Take a look and let me know your thoughts, I’d be happy to help out however I can.
Healthline is interested in contributing a guest post to marilynmann.wordpress.com. We would be open to contributing any blog that would be of interest to your readers. Healthline bloggers have been featured on a variety of sites including:
Washington Times: http://communities.washingtontimes.com/neighborhood/tango-mind-and-emotion/2012/aug/10/how-healthy-choices-easy/
Natural News: http://www.naturalnews.com/036515_diabetes_strawberries_prevention.html
Please let me know if you have any questions. Thank you in advance for your consideration.
Thanks, but I decline the offer.
I hope all is well.
I wanted to reach out to you in regards to guest blog posting. The folks at Ubiquinol.org have written a post focusing on statin drugs and the side effects those drugs have on Ubiquinol Levels in the body.
Would you be interested in taking a look? He article isn’t published anywhere else, and we would love to share it with you.
Looking forward to your thoughts.
I’m sorry, but I’m not interested.
Pingback: Elektrische Zahnbuerste
Pingback: Excellent Observation: From A Friend Of The Blog | Health Wiki information